11 Nov , 2026 By : Shambhavi Mishra
? Quick Take: Kerala will make the costly SMA drug Risdiplam free in every district. This reduces the financial burden on families and sets a precedent for state-level healthcare subsidies.
The state government has announced that Risdiplam, a critical treatment for Spinal Muscular Atrophy (SMA), will be available free of cost to patients in all districts. This move eliminates the geographic barrier that previously limited access to the therapy, ensuring that every affected child in Kerala can receive life-saving medication without prohibitive out-of-pocket expenses.
Previously, accessing Risdiplam often required travel to major urban centers or specific government hospitals. By decentralizing the supply chain to district-level facilities, the state is removing logistical hurdles. For families in remote areas, this means shorter travel times and reduced secondary costs associated with treatment.
The drug itself is expensive, often costing lakhs per month. By absorbing this cost, the government is effectively treating it as a public health priority rather than a private luxury. This shift reflects a broader trend in Indian state governance where targeted subsidies for rare diseases are gaining traction.
Source Attribution: Originally reported by hindu-national (https://www.thehindu.com/news/national/kerala/free-risdiplam-for-sma-patients-to-be-made-available-in-all-districts/article71678866.ece).
Disclaimer: The financial, market, and corporate developments published above are reported for informational and educational purposes only. GrowMudra does not provide investment advice or stock recommendations. Readers are strongly advised to consult a SEBI-registered financial advisor before making investment decisions.
0 Comment